UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

Headache, 2020-07, Vol.60 (7), p.1259-1272

2020

Volltextzugriff (PDF)

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

Cephalalgia, 2014-10, Vol.34 (11), p.853-869

2014

Volltextzugriff (PDF)

Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity

The Journal of urology, 2012-06, Vol.187 (6), p.2131-2139

2012

Volltextzugriff (PDF)

Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact

Medicine (Baltimore), 2023-07, Vol.102 (S1), p.e32363-e32363

2023

Volltextzugriff (PDF)

Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowning

Scientific reports, 2023-02, Vol.13 (1), p.3333-3333, Article 3333

2023

Volltextzugriff (PDF)

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

Headache, 2010-06, Vol.50 (6), p.921-936

2010

Volltextzugriff (PDF)

Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30‐year experience

The Laryngoscope, 2018-01, Vol.128 (S1), p.S1-S9

2018

Volltextzugriff (PDF)

Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD

Cephalalgia, 2022-08, Vol.42 (9), p.933-943

2022

Volltextzugriff (PDF)

Update on Non-Interchangeability of Botulinum Neurotoxin Products

Toxins, 2024-06, Vol.16 (6), p.266

2024

Volltextzugriff (PDF)

Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients

The Laryngoscope, 2015-08, Vol.125 (8), p.1751-1757

2015

Volltextzugriff (PDF)

BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDY

The Journal of urology, 2005-07, Vol.174 (1), p.196-200

2005

Volltextzugriff (PDF)

Entering the 4th decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine

Medicine (Baltimore), 2023-07, Vol.102 (S1), p.e32370-e32370

Brin, Mitchell F

2023

Volltextzugriff (PDF)

Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX ® ) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis

Toxins, 2023-05, Vol.15 (5), p.342

2023

Volltextzugriff (PDF)

The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial

EClinicalMedicine, 2020-07, Vol.24, p.100429-100429, Article 100429

2020

Volltextzugriff (PDF)

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

Annals of neurology, 2003-09, Vol.54 (3), p.403-414

2003

Volltextzugriff (PDF)

Botox (onabotulinumtoxinA) mechanism of action

Medicine (Baltimore), 2023-07, Vol.102 (S1), p.e32372

2023

Volltextzugriff (PDF)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)

Medicine (Baltimore), 2023-07, Vol.102 (S1), p.e32373-e32373

2023

Volltextzugriff (PDF)

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact

Medicine (Baltimore), 2023-07, Vol.102 (S1), p.e32403-e32403

2023

Volltextzugriff (PDF)

Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies

Headache, 2017-01, Vol.57 (1), p.109-125

2017

Volltextzugriff (PDF)

Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA

Toxins, 2020-10, Vol.12 (10), p.661

2020

Volltextzugriff (PDF)

Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants

Journal of the American Academy of Dermatology, 2009-12, Vol.61 (6), p.961-970.e11

2009

Volltextzugriff (PDF)

Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: A randomized controlled trial

Journal of the American Academy of Dermatology, 2023-12, Vol.89 (6), p.1317-1319

2023

Volltextzugriff (PDF)

Versatility of OnabotulinumtoxinA in Aesthetic Medicine

Dermatologic surgery, 2024-09, Vol.50 (9S), p.S12-S17

2024

Volltextzugriff (PDF)

Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?

Cephalalgia, 2016-08, Vol.36 (9), p.875-886

2016

Volltextzugriff (PDF)

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact

Medicine (Baltimore), 2023-07, Vol.102 (S1), p.e32374-e32374

2023

Volltextzugriff (PDF)

1 – 25 von 267

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(217)

Publikationsform

Artikel
(252)
Buchkapitel
(12)
Bücher
(3)

Sprache

Englisch
(266)

Erscheinungsjahr

n.n

Thema

Science & Technology
(170)
Life Sciences & Biomedicine
(168)
Humans
(135)
Neurosciences & Neurology
(82)
Female
(79)
Clinical Neurology
(78)
Biological And Medical Sciences
(77)
Male
(77)
Medical Sciences
(75)
Adult
(68)
Middle Aged
(57)
Neurology
(54)
Botulinum Toxin
(43)
Aged
(38)
Botulinum Toxins, Type A - Therapeutic Use
(35)
Neurosciences
(30)
Neuromuscular Agents - Therapeutic Use
(25)
Child
(24)
Treatment Outcome
(24)
Otorhinolaryngology
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Movement Disorders
(33)
Toxicon
(22)
Neurology
(13)
Medicine
(11)
Headache
(10)
Muscle & Nerve
(9)
Otolaryngology-Head And Neck Surgery
(9)
The Laryngoscope
(9)
Cephalalgia
(8)
Pm & R
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor Overactivity

Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact

Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowning

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30‐year experience

Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD

Update on Non-Interchangeability of Botulinum Neurotoxin Products

Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients

BOTULINUM TOXIN TYPE A IS A SAFE AND EFFECTIVE TREATMENT FOR NEUROGENIC URINARY INCONTINENCE: RESULTS OF A SINGLE TREATMENT, RANDOMIZED, PLACEBO CONTROLLED 6-MONTH STUDY

Entering the 4th decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine

Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX ® ) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis

The effects of intensive speech treatment on intelligibility in Parkinson's disease: A randomised controlled trial

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

Botox (onabotulinumtoxinA) mechanism of action

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact

Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies

Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA

Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants

Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: A randomized controlled trial

Versatility of OnabotulinumtoxinA in Aesthetic Medicine

Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact

Suchergebnisse filtern